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Background: Bloodstream infection by Candida species has a high mortality in Latin Amer-
ican  countries. The aim of this study was to describe the characteristics of patients with
documented  bloodstream infections caused by Candida species in third level hospitals and
determine  the risk factors for in-hospital-mortality.
Methods: Patients from seven tertiary-care hospitals in Bogotá, Colombia, with isolation of a
Candida species from a blood culture were followed prospectively from March 2008 to March
2009.  Epidemiologic information, risk factors, and mortality were prospectively collected.
Isolates  were sent to a reference center, and ﬂuconazole susceptibility was tested by agar-
based E-test. The results of susceptibility were compared by using 2008 and 2012 breakpoints.
A  multivariate analysis was used to determinate risk factors for mortality.
Results:  We  identiﬁed 131 patients, with a median age of 41.2 years. Isolates were most
frequently  found in the intensive care unit (ICU). Candida albicans was the most prevalent
species  (66.4% of the isolates), followed by C. parapsilosis (14%). Fluconazole resistance was
found  in 3.2% and 17.6% of the isolates according to the 2008 and 2012 breakpoints, respec-
tively.  Fluconazole was used as empirical antifungal therapy in 68.8% of the cases, and
amphotericin  B in 22%. Hospital crude mortality rate was 35.9%. Mortality was  associated
with  age and the presence of shock at the time of Candida detection. Fluconazole therapy
was  a protective factor for mortality.
Conclusions: Candidemia is associated with a high mortality rate. Age and shock increasemortality,  while the use o
tance  rate with new break
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Introduction
Candidemia is the main invasive fungal infection that occurs
in  hospitalized patients; Candida species account for almost
80%  of fungal pathogens causing nosocomial infections.1 The
incidence  of candidemia has increased more  than ﬁve-fold in
the last decade.2 Recent data show an overall incidence of can-
didemia  ranging from 0.2 to 0.5 cases per 1000 admissions.3 An
incidence ranging from 0.28 to 0.96 cases per 1000 admissions
has  been found in the United States; in Europe, an incidence of
0.2–0.38  cases per 1000 admissions is estimated.4 Recently, an
incidence of 1.18 cases per 1000 admissions was  found in Latin
America;  in particular, the highest incidence was  found in
Colombia,  with 1.96 cases per 1000 admissions,5 much  higher
than  the reported incidences in the northern hemisphere,
with a trend to increase over the last decade.
Candidemia is associated with prolonged hospital stay,
increased costs, and a higher mortality rate that can vary from
25%  to 60%.6 In Latin America, particularly in Colombia, there
is  little information on epidemiological and clinical aspects
of  patients with candidemia. The present study describes the
clinical  and epidemiological characteristics of patients with
candidemia  in Colombian tertiary-care hospitals. The dis-
tribution  of species, their ﬂuconazole susceptibility proﬁle,
mortality  rates, and a multivariate statistical analysis of fac-
tors  associated with mortality are presented.
Materials  and  methods
Study  design
This was  an observational, multicenter study conducted over a
period of 12 months on patients who  had experienced at least
one  episode of candidemia between March 8, 2008 and March
7,  2009 in seven tertiary-care hospitals of Bogotá, Colombia.
Hospitals that participated in the study after having approved
the  research protocol were: Instituto Nacional de Cancerología
(INC),  Hospital Universitario San Ignacio (HUSI), Hospital de
San  José (HSJ), Fundación CardioInfantil (FCI), Hospital Uni-
versitario  Clínica San Rafael (HUCSR), Hospital Militar Central
(HMC),  and Hospital Universitario de la Samaritana (HUS). All
of them were  high complexity institutions, with intensive care
units (ICU, approximately 165 beds), internal medicine and
surgery  wards. One of them was  a reference center for can-
cer  (INC), and four of them had an oncology/hematology ward
(INC,  HUSI, HSJ, HMC). Three of them were  public (INC, HMC,
HUS).
Procedures
The study included all patients of any age group admitted
to  participating institutions during the study period with a
diagnosis  of infection with yeast of the genus Candida in
blood,  conﬁrmed by microbiology. The clinical laboratories of
the  institutions included in the study identiﬁed and typiﬁed
the  presence of Candida in blood cultures using automated
methods (BACTEC, Becton Dickinson, USA). The isolates of
Candida  species were  referred to the Instituto Nacional de 1 4;1  8(6):631–637
Cancerología,  where the strains were typed again in the mycol-
ogy  laboratory (Yeast ID, MicroScan, Dade Behring, Siemens,
USA)  and their susceptibility to ﬂuconazole was  tested by the
agar  based E-test method. At the same time, epidemiological
and clinical information of the patients were  prospectively
collected, and the patients were followed until discharge or
death.
Study  variables  and  deﬁnitions
Epidemiological variables, inpatient services, and inpatient
days  were included. The clinical variables and risk factors
were  the presence of various comorbidities (tumors, dia-
betes,  chronic renal insufﬁciency, etc.), systemic inﬂammatory
response syndrome (SIRS), organ dysfunction, or shock at
diagnosis  of candidemia. The main recorded microbiological
variable was  blood culture positivity time from sampling to the
report  from the blood culture team. We  also recorded several
treatment  variables. An episode of candidemia was deﬁned as
the isolation of a Candida species from one or more  blood cul-
tures.  The age ranges were  deﬁned as neonates: ≤28 days old
or  staying in the Neonatal Intensive Care Unit (for the pre-
mature);  children: age over 28 days up to 18 years; adults:
between 19 and 60 years; elderly: ≥60 years. For the num-
ber  of organs involved, the Score Organic Failure (SOFA) scale
was  used. Abdominal surgery was  deﬁned as a recent surgical
procedure  that involved the gastrointestinal tract within the
last  two weeks. Prolonged corticotherapy was  deﬁned as doses
>0.5  mg/kg/day of prednisone or equivalent corticosteroid or
cumulative dose higher than 700 mg.  Previous ﬂuconazole
exposure was  any hospital use of ﬂuconazole seven days
before  the blood cultures were  taken in which the Candidia
species  was  isolated. The interpretation of susceptibility to
ﬂuconazole  was  initially performed with breakpoints from the
Clinical  Laboratory Standards Institute (CLSI), 2008 (CLSI 2008)
where  a minimum inhibitory concentration (MIC) ≤8 mg/L is
considered susceptible (S), ≥64 mg/L resistant (R), and inter-
mediate  values susceptible dose-dependent (SDD). A posteriori
analysis  taking into account the existing cutoffs proposed by
Pfaller et al. in 20127 was conducted. For C. albicans, C. para-
psilosis,  and C. tropicalis, S was deﬁned as a MIC  ≤ 2 mg/L, R a
MIC  ≥ 8 mg/L, and SSD intermediate MIC values. For C. glabrata,
MIC  ≤ 32 mg/L was  considered SDD, and MIC ≥ 64 mg/L were
considered R. Inappropriate use of ﬂuconazole was  deﬁned as
the use of ﬂuconazole in patients with resistance to ﬂucona-
zole  by susceptibility testing. Mortality was  assessed at 14 days
after detection of candidemia and hospital mortality.
Statistical  analysis
For descriptive analyses mean and standard deviation (SD)
for  continuous variables and percentages for categorical data
were  calculated. For evaluating association between mortality
and  demographic and clinical variables, preliminary univari-
ate  analyses were performed calculating crude odds ratios
(ORs).  A multivariate analysis of all factors found to be signiﬁ-
cant  on univariate analysis and of the most clinically relevant
variables  was  performed to estimate adjusted ORs. Statistical
analyses  were performed with Stata 11. All reported p-values
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Table 1 – Demographic and clinical features in patients
with  candidemia (n = 131).
Variable Episodes
n  (%)
Age in years, average (S.D.) 41.2  (25)
Neonates 15 (11.4)
Children 12 (9.16)
Adults 69 (52.6)
Elderly 35 (26.7)
Men 80 (61.1)
Hospital service
ICU  59 (45.0)
Floor 52 (39.6)
NICU 13 (9.9)
PICU 6 (4.5)
Emergencies 1 (0.7)
Basal condition
Use  of antibiotic 101 (77.1)
Recent abdominal surgery 54 (41.2)
Use of steroids 39  (29.8)
Neoplasia 34 (26)
Solid tumor 21  (16)
Leukemia 10 (7.6)
Lymphoma 3 (2.3)
Diabetes mellitus type 2 17 (13)
Peripheral vascular disease 15 (11.5)
Chronic renal disease 12 (9.2)
Hemodialysis 8 (6.1)
Burn 2 (1.5)
HIV infection 1 (0.7)
Solid organ transplant 1 (0.7)
Clinical and laboratory response
SIRS  109 (83)
Leukocytosis 56 (43)
Leukopenia 15 (11)
Dysfunction of 3 or more organs 33 (25)
Shock 45 (34)
S.D., standard deviation; ICU, intensive care unit; NICU, neonatal
intensive care unit; PICU, pediatric intensive care unit, SIRS, sys-b r a z j i n f e c t d i s .
ere  two-sided and considered signiﬁcant when less than 0.05
onﬁdence intervals of 95% were  estimated.
esults
 total of 131 patients with candidemia were included in
he  study. The mean age was  41.2 years, with a standard
eviation (SD) of 25 years, ranging from 9 days to 87 years.
he  male:female ratio of these patients was  1.6:1. The inpa-
ient  service with the greatest frequency of isolates was  the
dult  ICU, with 45% (n = 59 patients), followed by the inpatient
oors,  with 39.6% (n = 52 patients). The mean duration of hos-
italization  was  53 days (range 3–219 days). In total, 78.6%
f  patients had been to the ICU at some point during their
ospitalization (n = 103 patients) and had an average ICU stay
f  29 days (range 1–125 days). The mean time from hospital
dmission to a later identiﬁcation of candidemia was  24 days
range  1–101 days). To perform blood cultures, the most used
enipuncture site was  the peripheral vein, in 75.5% of cases
n  = 99 patients). Seventy-three patients (55.7%) had a single
ositive  blood culture, 46 (35.1%) two positive blood cultures,
nd  12 (9.1%) three positive blood cultures. On average, blood
ultures  yielded positive results 36.3 h after collection (range
–5  days; 90th percentile = 56 h). In 51 (38.9%) patients, bac-
eremia  was  documented by blood culture in the days prior.
ram-positive cocci were  the most frequent type of isolated
acteria  (n = 23 patients, 45.2%), followed by Gram-negative
acilli (n = 20, 39.2%). Polymicrobial bacteremia was  identiﬁed
n  8 (15.7%) patients. Some epidemiological ﬁndings are sum-
arized  in Table 1.
A  total of 137 isolates of Candida species were found in the
31  patients; 6 patients (4.6%) presented mixed yeast infection.
he  most common species among monomicrobial isolates
as  C. albicans, in 87 (66.4%) patients, followed by C. parap-
ilosis  in 19 (14.5%), and C. tropicalis in 14 (10.6%). Six cases of
ixed  infections were  found: three cases of C. albicans and C.
ropicalis  infection, and three cases of mixed infections with
.  parapasilopsis (C. albicans, C. famata, and C. tropicalis, each
ne).  Species distribution according to age groups is shown in
able  2 and no statistical differences were seen among those
roups.  Sixty-eight patients (51.9%) were adults. The global
ortality  rate was  35.9% (n = 47 patients) and was  higher in
he  group of elderly people (n = 22, 61.1%). The mortality rate in
he group of patients with C. albicans was  37.9% (n = 33), while
hose  with non-albicans Candida (NAC) species had a mortal-
ty  rate of 31.5% (n = 12). The mortality rate in the group of
ixed  infections was  33.3% (n = 2). Mortality rate was  higher
n  C. glabrata and C. lusitanae cases (100%), than in C. parap-
ilopsis  and C. tropicalis cases (26.3% and 28.5%, respectively).
he two cases of C. guillermondii survived. There was  no sig-
iﬁcant  difference in mortality rates among different Candida
pecies.  Mortality was  higher among those aged more  than
0  years old (61.1%), than adults (39.4%), children (16.6%), and
eonates  (11.4%) (p < 0.05 for the comparison between eldery
nd  the other age groups).The  susceptibility proﬁle to ﬂuconazole was  identiﬁed with
he  breakpoints from the CLSI-2008 and those proposed in
012  by Pfaller et al. For this analysis, 125 isolated species
ere  considered (the six cases of mixed infection were nottemic inﬂammatory response syndrome.
included). The average MIC for ﬂuconazole was  0.87 mg/L for
all  single isolates, and the MIC90 was  14 mg/L. For C. albicans, a
mean  MIC  for ﬂuconazole of 0.5 mg/L was  found, with a MIC90
of 5.28, while for C. parapsilosis and C. tropicalis, the average
MIC  was  3.9 mg/L and 2.85 mg/L, and the average MIC90 was
29  mg/L and 15 mg/L, respectively. Table 3 shows ﬂuconazole
susceptibility testing by the E-test with the two breakpoints.
Fluconazole susceptibility differed signiﬁcantly when the dif-
ferent breakpoints were  used. With the CLSI-2008 breakpoints,
103  (82.4%) isolates were S, 18 (14.4%) were  SDD, and 4 (3.2%) R.
Considering  the 2012 breakpoints, 86 (68.8%) isolates were  S, 17
(13.6%)  were SDD, and 22 (17.6%) were R. With the CLSI-2008
breakpoints, 6.8% (n = 6) of isolates were SDD or R; with the
new  cutoffs, this percentage rose to 17.2% (15 isolates). Sim-
ilarly,  NAC  species presented higher frequency of SDD and R
with the new breakpoints, changing from 12.8% (16 isolates)
to  19.2% (24 isolates). Nine patients have received ﬂuconazole
at  least one week before Candida isolation. The mean MIC was
higher  (21.3 mg/L vs. 7.3 mg/L) for those isolates from patients
634  b r a z j i n f e c t d i s . 2 0 1 4;1  8(6):631–637
Table 2 – Frequency of identiﬁed species by age group.
Neonates
n  (%)
Children
n (%)
Adults
n  (%)
Elderly
n  (%)
Total
n (%)
C. albicans 9 (60) 8 (67) 45 (66.1) 25 (69.4) 87 (66.4)
C. parapsilosis 2 (13.3) 4 (33) 10 (14.7) 3 (8.3) 19 (14.5)
C. tropicalis 2 (13.3) 9 (13.2) 3 (8.3) 14 (10.6)
C. glabrata 1 (1.4) 1 (2.7) 2 (1.5)
C. lusitaniae 1 (2.7) 1 (0.8)
C. guillermondii 2 (2.9) 2 (1.5)
Mixed infections 2 (13.3) 1 (1.4) 3 (8.3) 6 (4.5)
Total 15 (11.4) 12 (9.1) 68 (51.9) 36 (27.4) 131 (100)
Table 3 – Susceptibility to ﬂuconazole in monomicrobial isolates identiﬁed by E-test with the 2008 and 2012 breakpoints.
Species Frequency
n  (%)
Susceptibility  breakpoints 2008
n  (%)
Susceptibility  breakpoints 2012
n  (%)
S SDD R S SDD R
C. albicans 87 (69.6) 81 (93.1) 3 (3.4) 3 (3.4) 72 (87.7) 8 (9.2) 7 (8)
C. parapsilosis 19 (15.2) 11 ((58.8) 8 (42.1) – 6 (31.6) 5 (26.3) 8 (42.1)
C. tropicalis 14 (11.2) 9 (64.2) 5 (35.7) – 7 (50) 2 (14.2) 5 (35.7)
C. glabrata 2 (1.6) – 2 (100) – – 1 (50) 1 (50)
C. guillermondii 2 (1.6) 1 (50) – 1 (50) – 1 (50) 1 (50)
C. lusitaniae 1 (0.8) 1 (100) – – 1 (100) – –
Total 125 (100) 103 (82.4) 18 (14.4) 4 (3.2) 86 (68.8) 17 (13.6) 22 (17.6)S, susceptible; SDD, susceptible dose-dependent; R, resistant.
that had received ﬂuconazole, but the difference was not sta-
tistically  signiﬁcant (p = 0.063).
In  total, 109 patients received antifungal treatment (includ-
ing  the six with mixed infections), of whom 44 (40%) started
treatment before a positive blood culture result. The other 65
(60%)  patients started treatment after blood culture results
were  known. The most widely used antifungal was  ﬂucona-
zole,  in 75 (68.8%) cases, followed by amphotericin B in 24
(22%),  caspofungin in 9 (8.2%), and itraconazole in 1 (0.9%). In
the case of C. albicans (71 patients), the most used antifungal
was  ﬂuconazole, in 51 (71.8%) patients, followed by ampho-
tericin  B in 12 (16.9%) and caspofungin in 7 (9.8%). In the case
of  NAC (32 patients), the most used antifungal was  ﬂucona-
zole,  in 20 (62.5%) patients, followed by amphotericin B in 10
(31.3%)  and caspofungin in 2 (6.2%). Similarly, the most used
antifungal  in the case of mixed infections (six patients) was
ﬂuconazole  in three patients (50%). Sixty-two (56.8%) received
only  one antifungal, and 33 (30.2%) received two antifungals
during their hospital stay. The most frequent changes were
ﬂuconazole to amphotericin B and from ﬂuconazole to caspo-
fungin,  both in 9 (27.2%) patients, followed by amphotericin B
to ﬂuconazole in 5 (15.1%). The average duration of antifungal
treatment before any change or addition was  10 days (range
0–49  days). A third antifungal was  used in 14 (12.8%) patients.
Of  the 14 patients who used three antifungals, 4 (28.5%) pre-
sented  mixed infection, 9 (64.2%) were infected with NAC, and
1  (7.1%) was  infected with C. albicans. When considering the 71
patients  with monomicrobial infection who were treated with
ﬂuconazole,  inappropriate use of ﬂuconazole increased from
2%,  0%, and 0% to 5.8%, 46.1%, and 25% for patients infected
with  C. albicans, C. parapsilosis, and C. tropicalis, respectively.
The  increases were  signiﬁcant for C. parapsilosis and C. tropi-
calis  (p < 0.05).The mortality rate at 14 days after diagnosis of candidemia
was  19.8% (26 cases), while mortality rate until the time of
discharge  was  35.9% (47 cases). In the group of patients who
received  antifungal therapy (109 patients), hospital mortality
rate  was 33.9%, while mortality in patients who  received no
treatment  (22 patients) was  45.4% (OR 1.6; 95% CI 0.6–4.0). Mor-
tality  among patients with NAC and patients with C. albicans
was  31.5% and 37.9%, respectively. Signiﬁcant variables iden-
tiﬁed  and included in the multivariate model were  shock,
dysfunction of three or more  organs, neutrophilia (peripheral
blood  neutrophils >7500/mm3), solid tumor, and abdominal
surgery (Table 4). When performing the multivariate logistic
regression, age (OR 1.03; 95% CI 1.01–1.05) and the presence
of  shock (OR 5.05; 95% CI 1.96–13) at diagnosis were  identiﬁed
as  the only variables independently associated with mortality.
The  use of ﬂuconazole was  a protective factor for mortality (OR
0.23;  95% CI 0.07–0.70).
Discussion
Our results conﬁrm previous ﬁndings with respect to the epi-
demiology  of candidemia in Colombia and its high mortality
rate.  A surveillance study of seven Latin American countries
included information on Colombia, and patients there had
lower  mean age than in other countries but similar frequen-
cies  of other comorbidities, such as cancer and diabetes.5 A
similar  mean age and rates of cancer and diabetes to those
identiﬁed in a multicenter study in Brazil were also observed.8An advantage of the present study is that it provides informa-
tion  from a larger number of hospitals in Colombia. The overall
mortality  rate at discharge in our clinical series was 35.9%,
similar  to the 31.4% described in Japan9 and 44% in Spain,10
b r a z j i n f e c t d i s . 2 0 1 4;1 8(6):631–637  635
Table 4 – Predictors of mortality in bivariate and multivariate logistic regression analysis.
Variable Outcome Univariate model Multivariate model
Dead
n = 47
Alive
n = 84
OR  95% CI OR 95% CI
Age (median in years) 60  30 4.4 1.9–9.8 1.03 1.017–1.058
Shock 26 19 4.2 1.9–9.1 5.05 1.96–13.01
Dysfunction of 3 or more organs 20 13 4.0 1.7–9.2 2.56 0.93–6.98
Solid tumor 12 10 2.5 1.0004–6.4 2.94 0.93–9.2
Treatment 72 37 2.3 0.9–5.9 3.18 0.76–13.2
Use of ﬂuconazole (empirical) 23 52 0.5 0.28–1.2 0.23 0.07–0.70
Resistance 2008a 1 3 0.5 0.05–5.7 0.54 0.03–7.6
Resistance 2012a 9 13 1.2 0.5–3.3 1.65 0.53–5.15
Abdominal surgery 25 28 2.2 1.09–4.7 – –
Hemodialysis 5 3 3.2 0.7–14 – –
Type 2 diabetes mellitus 9 8 2.2 0.8–6.1 – –
Peripheral vascular disease 8 7 2.2 0.7–6.6 – –
Use or steroids 18 21 1.8 0.8–4 – –
Leukocytosis 24 32 1.6 0.8–3.4 – –
Stay in ICU 39 63 1.6 0.6–4 – –
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(OR, odds ratio; 95% CI, 95% conﬁdence interval.
a For this analysis, the six mixed infections were not included (n = 12
ut lower than that reported in Brazil, which varied between
4%  and 61%,8,11 or Italy, at 54%.2 It is also slightly lower than
hat  identiﬁed in the aforementioned Latin American study.5 A
ecent multicenter study suggests that mortality attributable
o  candidemia has increased by approximately 30% in the ICU
nd  by approximately 10% in inpatient services.12
The present study found that the majority of isolates were
.  albicans, and C. parapsilosis, and C tropicalis were  the most
ommon  NAC species. The Latin American study,5 as well as
revious  studies in Colombia,13,14 reported similar ﬁndings,
lthough with a tendency toward more  NAC species. In Brazil,
he  species most frequently identiﬁed was  C. albicans, followed
y  C. parapsilosis and C. tropicalis.8,11 In other geographic areas,
uch  as in India,20 NAC predominates, with a prevalence of
8%.  In Taiwan,21 69.6% of isolates are NAC, with C. tropicalis
nd  C. glabrata being the most frequent. These ﬁndings con-
rm  the increased frequency of C. tropicalis and C. parapsilosis
mong  species of NAC in Latin American.15
We  chose to assess susceptibility to ﬂuconazole by E-test
ecause  in previous studies this showed good correlation with
he  standard methods, with a low frequency of minor and
ajor  errors.16 However, this method has shown higher MICs
ompared  to the standard microdilution methods, ranging
rom  2- to more  than 6-fold higher.16 Another study that com-
ared  the same methods found smaller differences between
he  E-test and the standard test, with a level of agreement
93% and with smaller difference between the MICs, espe-
ially  among the C. albicans isolates.17 One of the problems
ith the comparisons is the use of different methods for mea-
uring  susceptibility. A microbiological study in Colombia13
ollected 2139 Candida isolates from different clinical sam-
les  and, using disk diffusion method, reported a resistance
ate  of 6.8%, with SSD strains constituting 5.1%. In the present
tudy,  using the E-test, we found a ﬂuconazole resistance rate
f  3.2% using the CLSI 2008 breakpoints. However, taking into
ccount  the new breakpoints proposed by Pfaller et al. in 2012
resistance  considered with MICs ≥ 8 mg/L), resistance up to17.6%  was  encountered. In the group of NAC, a signiﬁcant
increase in the frequency of resistant species was  observed.
One  study found higher MICs when the E-test was  used than
when  microdilution tests were used, especially with isolates
of  C. tropicalis and other less common species of Candida.18
This change in the susceptibility results had an impact on
the  frequency of inappropriate therapy, with an increase of
patients  with resistant isolates treated with ﬂuconazole. It is
possible that differences in the MICs obtained by the E-test are
relevant given the new breakpoints, which partially explains
the  high resistance rates identiﬁed. The previously mentioned
Latin  American study identiﬁed a low rate of resistance, even
with  the new breakpoints used for ﬂuconazole, although the
assessment  was performed using broth microdilution.5 There
is  still controversy about the clinical usefulness of the pro-
posed  breakpoints since there is a lacking of clinical data
to  validate them.7 A previous pharmacodynamic study has
shown  a good correlation between dose and MIC, a more  use-
ful  clinical information.19 There is still a need for clinical
validation of in vitro breakpoints and clinical interpretation
in  Candida species. A Spanish surveillance study compared
rates  of resistance to ﬂuconazole and other antifungals using
the  microdilution method with the previous breakpoints and
the  more  recently recommended breakpoints, without ﬁnding
important  differences in resistance rates.20 A study similar to
ours  conducted in Brazil,21 in a reference institution using the
E-test  for susceptibility testing, showed a rate of susceptibility
>97%, but 90% of the isolates had a MIC ≥ 4 mg/L, considered
dose-dependent with the new breakpoints for some species.
Another  reason we identiﬁed higher rates of resistance may
be  that we  included an oncology institution. The presence of
hematological  neoplasias is one of the few known predictors
of  resistance to ﬂuconazole.9,22
In our clinical series the most commonly used antifungal
in  patients was  ﬂuconazole, followed by amphotericin B, in
accordance  with what has been described in the rest of Latin
America5 and in contrast to rates identiﬁed in Brazil,11 where
i s . 2 0
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1
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amphotericin B predominated, followed by the azoles. It is
noteworthy  that 22 patients (16.8%) received no treatment.
There  was  no difference in mortality between treated and
untreated  patients, similar to the previous series in Brazil11
where 30% of patients received no treatment and mortality
did  not differ between treated and untreated. Other studies
have  identiﬁed a delay in the initiation of antifungal therapy
as  a predictor of mortality.23,24 Delays longer than 12–15 h after
the  identiﬁcation of positive blood cultures correlates with
an  increased risk of death in patients with candidemia. The
allowable  delay can be even shorter in patients identiﬁed to
be  in shock at the time of candidemia.25 Although our study
shows  that the use of ﬂuconazole was  associated with lower
mortality,  this result may  have been related to less frequent
use  of other antimycotic agents. In the current recommenda-
tions in unstable patients, an echinocandin is preferred for its
lower associated mortality and better safety proﬁle compared
to  azoles and amphotericin, respectively.4,26
Our multivariate analysis showed that age and presence
of  shock at diagnosis of candidemia were signiﬁcantly asso-
ciated  with mortality. In another series,27 APACHE II score,
steroid  use, inadequate dose of ﬂuconazole, and indwelling
central venous catheter were independent factors associated
with  mortality. In studies in Brazil11 and Italy,2 APACHE II score
has  also been independently associated with mortality. Impor-
tantly,  our multivariate analysis found that despite the new
breakpoints,  ﬂuconazole resistance was  not associated with
mortality,  and treatment (grouping together all antifungals)
was  not associated with mortality. However, it must be high-
lighted  that the use of initial therapy with ﬂuconazole was
a  signiﬁcant protective factor, reducing mortality by approxi-
mately  30%.
There  are limitations to our study. Although tertiary-care
hospitals were chosen, these hospitals are all located in the
same  city and therefore results might not generalizable to
Colombia  as a whole. However, there is limited information
in  Colombia of surveillance studies, so this contribution can
be  signiﬁcant. It is also important to note that despite the fact
that  SOFA deﬁnitions were  used for estimating the number of
failing  organs, neither SOFA score itself nor other prognostic
index  were  used. In addition, the method considered standard
for  measuring susceptibility was  not used (considering either
CLSI  or EUCAST methodology), and resistance may  have been
overestimated. As mentioned before, it limits the possibility
of  comparing our results with previous studies or the study of
Latin  American countries.
In  conclusion, we  found that bloodstream infection by Can-
dida  species followed the same patterns of risk in Colombia
as  elsewhere in Latin America, with shock and age being
predictors of mortality. The identiﬁed isolates had low sus-
ceptibility  to ﬂuconazole, which may  have been secondary
to  the assessment method, the change in breakpoints, or a
real  decrease in susceptibility observed over time, especially
considering that the study population included an oncology
institution.Conﬂicts  of  interest
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